Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN Clinical Practice Guidelines for myeloproliferative neoplasms (MPNs) and who the recommendations will transition over the next year. Mesa spoke on the topic during an interview at the 34th Annual Chemotherapy Foundation Symposium™, held November 9-11, 2016 in New York City.
Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL
June 9th 2023Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Pelabresib Leads to Hematologic Response in Hydroxyurea-Refractory or Intolerant High-Risk ET
June 9th 2023Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.
Read More
Teclistamab Follow-Up Data Yields Consistent Results in Relapsed/Refractory Multiple Myeloma
June 9th 2023At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.
Read More
2 Clarke Drive
Cranbury, NJ 08512